Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Drug interactions between Adcetris and Kadcyla

Results for the following 2 drugs:
Adcetris (brentuximab)
Kadcyla (ado-trastuzumab emtansine)

Interactions between your drugs

Moderate

brentuximab vedotin ado-trastuzumab emtansine

Applies to: Adcetris (brentuximab) and Kadcyla (ado-trastuzumab emtansine)

Brentuximab vedotin may cause nerve damage and liver problems, and using it with other medications that can also have these effects such as ado-trastuzumab emtansine may increase the risk. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should avoid or limit the use of alcohol while being treated with these medications. Let your doctor know if you experience burning, tingling, pain, numbness, or weakness. Also seek immediate medical attention if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Therapeutic duplication warnings

No therapeutic duplications were found for your selected drugs.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide